|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
We have observed highly elevated levels of all four isoforms of p38 MAPK in serum of HNSCC patients compared to the control group.
|
29747487 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
TCIP-H SCCHN tumors were associated with the MAPK/ERK, JAK/STAT and mTOR/AKT signaling pathways, and were enriched in CASP8, EP300, EPHA2, HRAS mutations, CD274, PDCD1LG2, JAK2 amplifications.
|
31422218 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that overexpressed PRRX1 was closely correlated with miR-642b-3p downregulation and the upregulation of TGF-β2 and p38 in a xenograft model of HNSCC.
|
30622052 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study demonstrated that p38 MAPK activation may play a role in therapeutic resistance and disease relapse in HNSCC by maintenance of CSCs phenotype.
|
29575240 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased FGFR3 signaling after selumetinib treatment.
|
30343534 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.
|
30115483 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC.
|
28915597 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, PD-L1 expression in HNSCC may be altered during cisplatin treatment, activating the MAPK/ERK kinase pathway.
|
29228662 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association analyses between the 800 candidate SNPs (covering 82 genes) and pain in a patient cohort of 1368 patients with HNSCC (206 patients with severe pain vs. 1162 with non-severe pain) showed the highest significance for MAPK1/ERK2, a gene belonging to the MAP kinase family (rs8136867, p value = 8.92 × 10(-4); odds ratio [OR] = 1.33, 95 % confidence interval [CI]: 1.13-1.58).
|
26872611 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
p38 inhibitor treated and p38 shRNA HNSCC cell lines demonstrate a significant upregulation in E-cadherin mRNA and a decrease in the mRNA expression of Snail. p38 binds to and stabilizes p38IP, a subunit of histone SPT3-TAF9-GCN5 acetyltransferase (STAGA), resulting in enhanced transcription of Snail. p38 shRNA HNSCC cell lines show a less invasive phenotype in a spheroid model.
|
27531877 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated increased AREG secretion in HNSCC cell lines harboring endogenous or exogenous MAPK1E322K compared to wild type MAPK1.
|
27004400 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
One potential therapeutic target for HNSCC is the RAS/RAF/MEK/ERK cascade, which is one of the major signaling pathways for HNSCC cell survival.
|
26053277 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.
|
24568968 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Since our previous data determined p38 MAPK to be a potent regulator of interleukin-6 (IL-6) and IL-8 expression in permanent head and neck squamous cell carcinoma (HNSCC) cell lines, we investigated the influence of this pathway on STAT3 and STAT1.
|
22110204 |
2011 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
Here we explored the use of an intercomplementing anthrax toxin that requires combined cell surface uPA and MMP activities for cellular intoxication and specifically targets the ERK/MAPK pathway for the treatment of HNSCC.
|
21655226 |
2011 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
Biomarker
|
disease |
BEFREE |
We found that the blocking activation of ERK and/or p38 could reverse the celecoxib-induced cell growth inhibition by 50-80% in HNSCC cell lines, but it was not tested in cancer cells of other types.
|
20717005 |
2010 |